Researchers cast doubt over benefits of new Alzheimer’s therapies – POLITICO
Eli Lilly and Biogen could not immediately be reached for comment. These drugs have also divided regulators. The U.S. Food and Drug Administration approved lecanemab last year and donanemab this year. Last month, however, the European Medicines Agency opposed a license for Leqembi — the brand name for lecanemab — arguing that the small benefits … Read more